In situ self-assembly for cancer therapy and imaging

J Kim, S Lee, Y Kim, M Choi, I Lee, E Kim… - Nature Reviews …, 2023 - nature.com
In situ self-assembly—the in situ formation of complex materials via biochemical reactions of
monomers—has enhanced the efficacy of drug delivery for cancer therapy and imaging. So …

Radiotheranostics in oncology: current challenges and emerging opportunities

L Bodei, K Herrmann, H Schöder, AM Scott… - Nature Reviews …, 2022 - nature.com
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management

JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Molecular imaging in oncology: Current impact and future directions

SP Rowe, MG Pomper - CA: a cancer journal for clinicians, 2022 - Wiley Online Library
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …

Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter …

TA Hope, M Eiber, WR Armstrong, R Juarez… - JAMA …, 2021 - jamanetwork.com
Importance The presence of pelvic nodal metastases at radical prostatectomy is associated
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

MJ Morris, SP Rowe, MA Gorin, L Saperstein… - Clinical Cancer …, 2021 - AACR
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …

[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)

R Seifert, L Emmett, SP Rowe, K Herrmann… - European Urology, 2023 - Elsevier
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …

[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …

S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi… - European urology, 2023 - Elsevier
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for …

KM Chow, WZ So, HJ Lee, A Lee, DWT Yap… - European urology, 2023 - Elsevier
Context Whether prostate-specific membrane antigen positron emission tomography (PSMA-
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …

[HTML][HTML] Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate-to very …

DS Surasi, M Eiber, T Maurer, MA Preston, BT Helfand… - European urology, 2023 - Elsevier
Abstract Background Radiohybrid (rh) 18 F-rhPSMA-7.3 is a novel high-affinity prostate-
specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) …